Fintech PR
Engagement Labs Releases FY 2018 Audited Results, Launches Prospectus Offering of approximately $1,800,000 in Units Led by Gravitas Securities, Proposes Debt Reorganization for approval by Debentureholders and 2:1 Share Consolidation
Reading Time: 5 minutes
Engagement Labs Inc. (TSXV: EL) (OTCQB: ELBSF) released results for its fiscal year ended December 31, 2018. Audited consolidated Financial Statements and Management Report are available on SEDAR’s website at www.sedar.com.
Fiscal Year 2018 Audited Results Released
- TotalSocial® revenue increased by 113% from year ended December 31, 2017 to year ended December 31, 2018.
- The number of brands using TotalSocial® increased to 20 during 2018, up from 9, and the number of industry sectors increased from 6 to 11. New sectors include Sports, Retail/Apparel, Beverage, Agency and Travel, to go along with Media, Beauty, Telecom, Software, Food and Financial.
- Total revenue, including both TotalSocial® and the Company’s legacy products, was $3,973,704 for the year ended December 31, 2018, an increase of 15% compared to $3,469,767 for the year ended December 31, 2017. In the US, year-over-year growth was 26%, while the UK saw a decline for the year.
- Gross profit increased by 25%, from $1,457,485 for the year ended December 31, 2017 to $1,818,527 for the year ended December 31, 2018. As a percentage of revenue, the gross margin increased by 4%, from 42% for the year ended December 31, 2017 to 46% for the year ended December 31, 2018.
- Non-GAAP Adjusted EBITDA loss increased by 20%, from –$2,684,152 for the year ended December 31, 2017 to –$3,228,681 for the year ended December 31, 2018. Operating expenses before extraordinary items increased by 18%, from $5,514,535 for the year ended December 31, 2017 to $6,533,005 for the year ended December 31, 2018.
- The net loss before income taxes for the year ended December 31, 2018 increased to –$5,628,884, up 26% or –$1,170,877 from –$4,458,007 for the year ended December 31, 2017. Basic and diluted loss per share was –$0.03 for the year ended December 31, 2018, compared to –$0.05 for the year ended December 31, 2017.
Fourth Quarter Financial Highlights
- TotalSocial® Revenue of $1,109,923 for Q4 2018 represents a 137% increase vs Q4 2017 of $467,908, and a 34% increase vs Q3 2018 of $829,739.
- Total revenue, including both TotalSocial® and the Company’s legacy products was $1,139,156 for Q4 2018, an increase of 29% from $883,342 in Q3 2018, and an increased of 15%, from $989,553 for Q4 2017.
- Gross margin increased to 54% in Q4 2018, from 40% in Q3 2018 and from 39% in Q4 2017.
- Operating expenses, before extraordinary items, have increased to $1,774,244 in Q4 2018, up 21% or $301,912 from $1,472,332 in Q3 2018, and up 5% or $83,644 from $1,690,600 in Q4 2017. The increase from 2017 reflects management’s commitment to invest in sales and marketing to drive TotalSocial® technology sales growth, including the hiring of a Chief Revenue Officer in late December 2017.
- Excluding extraordinary items and future income taxes, the net loss has increased to –$1,411,297 in Q4 2018, up 5% or –$61,745 from –$1,349,552 in Q3 2018, and down 9% or –$138,746 from –$1,550,043 in Q4 2017.
- EBITDA loss of –$1,012,039 for Q4 2018, representing an increase of $30,190, from –$981,849 for Q3 2018, and an increase of –$465,427, from –$546,612 for Q4 2017.
- Non-GAAP Adjusted EBITDA loss of –$735,594 for Q4 2018, representing an improvement of $11,838, from –$747,432for Q3 2018, and an improvement of $313,613, from –$1,049,207 for Q4 2017.
- Operating expenses increased 17% or $212,074 from Q3 2017. The increase from 2017 reflects management’s commitment to invest in sales and marketing to drive TotalSocial® technology sales growth, including the hiring of a Chief Revenue Officer in late December.
- Basic and diluted income per share was –$0.01 for Q4 2018 compared to –$0.01 for Q4 2017 and Q3 2018.
- As at December 31, 2018, the Company had cash (excluding restricted cash) of $906,455, compared to $2,677,049as of December 31, 2017.
“I said a year ago that 2018 is shaping up to be a transformative year for Engagement Labs as TotalSocial is now resonating with clients and prospects,” said Ed Keller, CEO. “Our year end results show the amount of progress we have made. We grew our number of clients and our range of sectors served.”
Corporate Restructuring
Proposed Share Consolidation and Amendment to Terms of Outstanding Debentures
Engagement Labs has mailed a Notice of Special Meeting of Shareholders providing for the proposed consolidation of the common shares of the Company on a two-for-one basis effective on or about May 27, 2019. The Meeting Materials also contemplate the approval of the issue of approximately 6,000,000 common shares on a post-consolidation basis at a price of $0.06 per share for fees owing to directors for 14 months of services for the period ended December 31, 2018. The payment in shares is to conserve cash of Engagement Labs and is subject to approval of the TSX Venture Exchange.
Engagement Labs has mailed a Notice of Meeting and Management Information Circulars (“Meeting Materials”) to holders of the 1% Debentures, and separate Meeting Materials to 2% Debentures, both of which series are due September 28, 2020. Engagement Labs is proposing to holders of 1% Debentures, of which there are approximately $4.23 million outstanding, and holders of 2% Debentures, of which there are approximately $1.6 million outstanding, to amend the terms of their debentures, subject to approval of 90% of the debentures outstanding of each series of debentures at a meeting or in writing, providing for the conversion of all of their outstanding debentures at a price of $0.11 per share for the 1% Debentures and $0.06 per share for the 2% Debentures, effective on or about May 27, 2019. These amendments, if approved, would cause all outstanding debentures to be cancelled and would substantially improve the Company’s financial position. The pricing of the conversion of the debentures is subject to final approval of the TSX Venture Exchange.
Prospectus Offering
The Company has entered into an agreement with Gravitas Securities Inc. (the “Agent”), pursuant to which the Agent has agreed to sell on a commercially reasonable efforts basis by short form prospectus, up to 30,000,000 units of the Company (the “Units”) at a price of $0.06 per Unit for aggregate gross proceeds to the Company of up to $1,800,000. Each Unit will be comprised of one common share of the Company, one-half of one common share purchase warrant (each such whole common share purchase warrant, a “$0.10 Warrant”) and a second one-half of one common share purchase warrant (each such whole common share purchase warrant, a “$0.12 Warrant”). Each $0.10 Warrant will be exercisable into one common share at an exercise price of $0.10 per share for a period of 6 months after the Closing Date (as defined herein). Each $0.12 Warrant will be exercisable into one common share at an exercise price of $0.12 per share for a period of 2 years after the Closing Date. The offering is subject to a minimum offering amount of $1,500,000.
The Company has also agreed to grant the Agent an over-allotment option to purchase up to an additional 4,500,000 Units at the offering price, exercisable in whole or in part, for a period ending 30 days from and including the Closing Date. In the event the over-allotment option is exercised in full, the aggregate gross proceeds of the offering will be $2,070,000.
The Units will be offered in each of the provinces of British Columbia, Alberta, Manitoba and Ontario by short form prospectus.
The offering is expected to close on or about May 27, 2019 (the “Closing Date”) and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the TSX Venture Exchange, the consolidation of the common shares of the Company on a two-for-one basis having occurred, the conversion of certain outstanding debentures of the Company in accordance with their terms and the issuance of a receipt for a final short form prospectus.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of Engagement Labs Inc. in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities offered have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the United States Securities Act of 1933, as amended, and applicable state securities laws or unless an exemption from such registration is available.
SOURCE Engagement Labs
Fintech PR
eCig Click Questions Impact of £10 Million Trading Standards Crackdown on Illicit Tobacco and Vaping Trade
MANCHESTER, England, April 17, 2025 /PRNewswire/ — In response to the UK government’s announcement of a £10 million funding package for Trading Standards to tackle illicit tobacco and vape sales, leading independent vaping platform eCig Click is raising questions about the strategy’s long-term effectiveness and value for money.
While the funding is meant to combat the sale of illegal products, eCig Click warns that the scale and complexity of the illicit market may render the investment insufficient and misguided.
Estimates suggest the UK loses tens of millions in tax revenue each year due to underground sales of vapes and tobacco – losses driven by overregulation, rising prices, and weak enforcement. In this context, the £10 million split between tobacco and vape enforcement could be seen as symbolic rather than systemic.
“This announcement may generate headlines, but does it address the root causes behind illicit sales?” said Jonny Carden, a spokesperson for eCig Click. “When regulated access is restricted and prices soar, black market operators fill the gap. Enforcement alone doesn’t fix flawed policy.”
The vaping industry has long called for balanced regulation, warning that excessive restrictions on legal products can unintentionally bolster the illegal market, putting consumers – especially youth – at greater risk. eCig Click cautions that restricting legal access without offering safe alternatives may exacerbate the very issues enforcement aims to solve.
eCig Click also questions whether on-the-ground enforcement is sustainable. With Trading Standards already stretched and local budgets tight, the impact of short-term crackdowns remains unclear.
“Without comprehensive reform – combining smart regulation, fair taxation, and public education – enforcement may treat the symptoms, not the cause,” Carden added. “We need a policy that reflects market realities, not just news releases.”
As further vaping restrictions are expected in 2025, eCig Click urges policymakers to ensure enforcement is part of an evidence-led approach – one that includes economic modelling, consumer behaviour analysis, and input from responsible industry voices.
For industry insights and ongoing coverage of UK vape regulation, visit: https://www.ecigclick.co.uk/.
About eCig Click
Established in 2010, eCig Click is a leading independent resource for vaping reviews, news, and education in the UK. Focused on product transparency and consumer awareness, the platform reaches millions annually and is a trusted voice in the vaping community.
View original content:https://www.prnewswire.co.uk/news-releases/ecig-click-questions-impact-of-10-million-trading-standards-crackdown-on-illicit-tobacco-and-vaping-trade-302432336.html
Fintech PR
Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies
- Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks
- Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed
- Fund to be listed on public markets in due course
- Led by highly experienced industry and investment executives Annalisa Jenkins and Nicholas Johnston
LONDON, April 18, 2025 /PRNewswire/ — Alis Biosciences (“Alis”), an investment fund focused on returning capital to investors that is currently trapped in listed, development-stage biotech companies, today formally launches. Founded by highly experienced industry and investment executives, Alis’ goal is to protect public shareholders’ funds while still supporting company management and boards.
Currently, there are nearly 300 listed, development stage life sciences and biotech companies worldwide that have experienced clinical, regulatory or commercial setbacks. These have trapped capital worth over USD$30 billion on their balance sheets, with market caps ranging from USD$5 million to USD$100 million and cash reserves ranging from USD$10 million to USD$400 million.
Alis offers public companies a range of innovative and adaptable structures to return capital to their shareholders, while providing a chance for any residual science and IP to be developed if appropriate. Alis will approach the board and management of each target company and mutually agree the optimum Alis structure to deploy. Alis will then seek to delist the company from the public market with the agreement of its shareholders in the normal way. Each delisted company’s cash and IP will be held in individual Special Purpose Vehicles (“SPV”) which are managed by Alis. Applicable cash will then be returned to shareholders immediately, with the IP either developed or sold using one of the following structures.
- Structure A returns most of the uncommitted cash to shareholders (e.g. 97%), with the company then sold back to certain shareholders or stakeholders who wish to further develop any residual science. Alis will retain a small stake with any upside from its stake shared across these shareholders.
- Structure B returns the vast majority of uncommitted cash to shareholders (e.g. 95%), leaving just enough to manage the structured wind-down of the company. Alis keeps the IP associated with this company. This process will be far quicker than any bankruptcy process.
In the near term, Alis will seek a public market listing that will allow it to offer a further Structure:
Structure C leaves enough cash in the acquiring vehicle (e.g. 40% of cash balance), to allow Alis to fund further clinical programmes, with the remaining 60% of cash immediately returned to shareholders along with an equity interest in Alis. The proceeds from any clinical success will then be retained by participating contingent value rights and by retaining shares in Alis.
Nicholas Johnston, Board Member and Founder of Alis Biosciences, commented: “We founded Alis Biosciences to alter the status quo, where tens of billions of dollars of investors’ funds are trapped in moribund listed life sciences and biotech companies. Our highly experienced team work collaboratively with shareholders, management, and boards, to provide the optimum mechanism to return capital to shareholders, while also allowing stakeholders the option to further develop residual science and IP where there is potential to do so. This is too big a problem to ignore and Alis is committed to providing a fresh solution.”
Annalisa Jenkins, Chair of Alis Biosciences added: “In this challenging financial market environment, there is a need for greater creativity to find answers to this USD$30 billion problem. This needs to be solved if capital is to be effectively recycled within the capital market ecosystem to finance exciting new science that has the potential to succeed and deliver investor returns.
“Public and private investors have expressed strong support for Alis Biosciences’ tailored approach, reflecting demand for a new solution to this longstanding problem. We firmly believe that our highly experienced and scientifically knowledgeable investment team can not only help to return value to shareholders but also develop any viable residual science.“
Frequently, following a clinical or regulatory set back, publicly listed life sciences and biotech companies experience an often immediate and sharp decline in their stock price, coupled with the immediate and consequent loss of stock liquidity. This leaves cash on their balance sheet far in excess of their current market capitalisation, no commensurate growth or limited alternative near-term clinical development prospects of success, and no efficient and timely mechanism to return cash to shareholders.
These companies often hope to develop another compound or product in their pipeline or merge with a private company, thereby heavily diluting shareholder equity. These alternatives typically have a very different investment case from the original programme, but investors are left with no option but to follow the direction of management or the board, while tens of millions of dollars of investor capital remains on the balance sheet. Even when a company files for bankruptcy, this process is time consuming and expensive, and further delays the return of any cash to shareholders while failing to adequately capture any residual value in the company’s IP.
About Alis Biosciences
Alis Biosciences (“Alis”) is an investment fund focused on returning capital to investors that is currently trapped in listed, development-stage biotech companies. Alis protects the interests of acquired company shareholders by providing a mechanism to return capital and resuscitate viable science, creating a novel and much-needed market safety net that may end up boosting investment in high tech healthcare.
Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 biotechs all of which have experienced setbacks – typically a failure in clinical trials of their lead programme or unsuccessful commercial launch. Following a sharp decline in their stock price, with the concurrent reduction in liquidity, these companies are left with cash on their balance sheet far in excess of their market capitalization, no commensurate growth or limited alternative near-term clinical development prospects of success; and importantly with no efficient and timely mechanism to return cash to shareholders.
Alis has a highly experienced and scientifically knowledgeable team that works collaboratively with shareholders, management, and boards. It has a flexible approach, with different innovative structures, all adaptable, which provide a mechanism to return capital to shareholders, while also allowing stakeholders the option to further develop residual IP if enough stakeholders, in collaboration with external advisors, suggest there is potential.
Multiomic analysis will be used to validate the residual IP within companies to determine whether a positive outcome is achievable. The feedback from this work, carried out over a relatively short period of time, will then be used to determine whether a different path forward is possible for any of the residual IP left within a particular company.
For more information, please visit: www.alisbiosciences.com
View original content:https://www.prnewswire.co.uk/news-releases/alis-biosciences-launches-fund-to-free-over-usd30-billion-of-capital-trapped-in-listed-development-stage-life-sciences-and-biotech-companies-302431959.html
DUBAI, UAE, April 18, 2025 /PRNewswire/ — Xlence, an international CFD broker with an expanding presence in, MENA, and Asia, officially launched the Xlence Academy, a multilingual teaching portal for traders to study forex concepts and trading tactics.
The Xlence Academy was established to deliver education that efficiently fosters trader development. This is backed by practical, expert-oriented courses that are not solely theoretical but applicable at all levels.
Structured Learning for Traders at Every Level
Aiming at the rising demand for clear, practical teaching, the Xlence Academy offers an educational system that guides traders from fundamental concepts to advanced strategies. The Academy helps users start trading or improve their skills by promoting long-term skill development to build confidence and security in learning.
Key Features of the Xlence Academy:
- Introduction to Forex
Covering execution, order classifications and currency pairs, it covers the principles of the forex market. - Fundamental Analysis
Learn how to include economic data, central bank policies, and world news in trading decisions by understanding how they affect market behaviour and present trading opportunities. - Technical Analysis
Investigate price action techniques, technical indicators, and chart patterns to allow you to define entry and exit positions. - Trading Strategies
Develop confidence with methodical strategy courses on risk management, trend tracking, and breakout approaches for different market situations.
More Than Education: A Foundation for Success
The Academy offers a reliable foundation based on expert knowledge and practical application in a market setting where trading errors can be expensive.
The Academy helps traders foster the psychological discipline and risk awareness required to succeed, in addition to technical proficiency, by providing a systematic path from beginner to advanced levels. This all-encompassing approach reflects Xlence’s principle that comprehension, consistency, and ongoing learning are the foundations of long-term success.
Xlence gives traders the tools to take charge of their journey, make wiser choices, and interact with international markets from a strong position through the Academy.
About Xlence
Xlence is an international CFD broker focused on delivering a comprehensive trading experience through transparency, innovation, and global market access. With a significant footprint across, MENA, and Asia, it strives to meet the diverse needs of contemporary traders while upholding the highest ethical standards.
For more information, visit www.xlence.com and explore our free educational resources to support your trading success. We encourage you to take advantage of these resources and start your journey towards becoming a more informed and strategic trader.
Trade with Xlence, Excel in Trading
All trading involves risk. It is possible to lose all your capital. You should consider whether you can afford to take the high risk of losing your money.
Logo: https://mma.prnewswire.com/media/2606624/Xlence_Dark_Logo.jpg
Media contact:
Nicolas Georgiou
info@xlence.com
+357 96199856
View original content:https://www.prnewswire.co.uk/news-releases/xlence-introduces-xlence-academy-to-help-traders-learn-and-grow-302431399.html
-
Fintech PR7 days agoAB Charity Foundation Launches to Pioneer a New Global Model for Public Good Driven by Institutional Trust and Technology
-
Fintech PR7 days agoUN Global Compact and private sector move to accelerate progress on SDGs in Africa
-
Fintech PR7 days agoAccount Payables and Receivables Application Market on a Steady Growth Path: Projected to Grow Through 2030 at CAGR 9.70%
-
Fintech PR7 days agoPhoenix Aviation Capital and AIP Capital Announce the Closing of a Pre-Delivery Payment Facility with up to $300 Million in Total Commitments
-
Fintech7 days agoFintech Pulse: Your Daily Industry Brief – April 11, 2025 (Featuring Synapse, Yotta, Citadel Securities, Block, Citi, Valley Bank)
-
Fintech PR6 days agoCGTN: President Xi’s Southeast Asia visits set to inject new impetus into regional development
-
Fintech PR7 days agoUkrainian employers federation calls for deepening economic integration between the European Union and Ukraine
-
Fintech PR7 days agoLow Code Application Development (LCAD) Platforms for Business Developers Market Disruptions: Riding a High-Growth Wave Through 2030 at CAGR 17.01%.